ELLENEllenbarrie Industrial Gases Limited
Chemicals · Chemicals · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Ellenbarrie Industrial Gases Limited manufactures and supplies industrial gases in India and internationally. The company operates in two segments, Sale of Gases and Project Engineering Services. It offers oxygen, nitrogen, argon, helium, hydrogen, carbon dioxide, nitrous oxide, acetylene, and specialty gases for steel, pharma, shipbuilding, fabrication, food processing, and healthcare sectors. The company also provides project engineering services, including design, engineering, supply, installation, and commissioning of tonnage. In addition, it engages in the supply, installation, and commissioning of medical gas pipeline systems; and supply of medical equipment to healthcare facilities. Further, it supplies medical equipment, such as emergency and transport ventilators; central sterilisation system; lung function testing systems; and electro-cardiograph machines. The company was incorporated in 1973 and is headquartered in Kolkata, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Profit growth: 16.5% YoY
- • Debt/Equity: 0.19
- • Promoter holding: 77.8%
- • RSI: 75
- • MACD: fresh bullish crossover
- • Price vs EMA21: above
- • Bollinger Squeeze signal (setup quality 62%)
- • Breakout with Volume signal (setup quality 65%)
Bull case
- • Profit growth: 16.5% YoY
- • Debt/Equity: 0.19
- • Promoter holding: 77.8%
- • RSI: 75
Bear case
- • Revenue growth: 6.0% YoY
- • ROCE: 8.2%
- • Distance from 52-week high: 32.1% below high
- • Volatility: 50% annualized
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: 6.0% YoY
- • ROCE: 8.2%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹16.95). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.